SecBot SecBot
PRESS-RELEASE ·Filed Mar 19, 2026

NRXP

NRx Pharmaceuticals, Inc.
NEUTRAL
Impact 3/10
Horizondays Processed8mo ago WireGlobeNewswire
Press release · Earnings
Actionable Insight • Neutral

Traders should await the earnings call for actual financial results and clinical development updates. Until then, no actionable data is available.

DirectionNeutral
Confidencemedium
Horizondays

How the stock moved after the report

NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$1.84
T+0 close · Mar 19, 2026 · via day close
Latest settled
+121.74%
T+60 · $4.08
Vs SPY
+107.40%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Mar 19 $1.84entry
  2. T+1 · 8mo ago +0.54%α +2.29% · $1.85
  3. T+5 · 8mo ago +29.35%α +31.56% · $2.38
  4. T+20 · 7mo ago +38.59%α +30.97% · $2.55
  5. T+60 · 5mo ago +121.74%α +107.40% · $4.08
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

NRx Pharmaceuticals announced it will host a conference call to discuss its fiscal year 2025 financial results and provide updates on its drug development programs, including NRX-100 and NRX-101. The press release contains no actual financial data, only forward-looking statements and procedural details about the earnings call.

Key Facts

  • NRx Pharmaceuticals will host an earnings call on March 24, 2026, to discuss FY2025 results.
  • No financial figures (revenue, EPS, etc.) were disclosed in the press release.
  • Company highlighted progress in drug development programs and regulatory designations for NRX-100 and NRX-101.
  • Forward-looking statements dominate the release; no material financial or operational data provided.

Financial Impact

No financial impact can be assessed, no quantitative results disclosed.

Risk Factors

  • Lack of disclosed financials increases uncertainty ahead of the call.
  • Forward-looking statements may create expectations that are not met during the actual call.

Market Snapshot

Exchange
Nasdaq

Investment Themes

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

DocumentAccession Number
PRESS-RELEASE Data (Synthetic)press-3258835

Track record

22 reports on NRXP

Performance horizon

8 of 13 bullish or bearish reports moved the stock their way by T+5. Best: +70.33% at T+60 after the Mar 30, 2026 report. 10 of 13 went positive at some point.

Filters
  1. Nov 5, 202611d ago DEFA14A Neutral 3/10 Entry $2.38 to $2.19 Now $2.15 −9.66% ▼ −7.98% −10.58% vs SPY
  2. Nov 5, 202611d ago DEF 14A Neutral 4/10 Entry $2.38 to $2.19 Now $2.15 −9.66% ▼ −7.98% −10.58% vs SPY
  3. Nov 2, 202614d ago 8-K Bullish 6/10 Entry $2.17 to $2.38 Now $2.15 −0.92% ▲ +9.68% +9.60% vs SPY
  4. Oct 30, 202617d ago Press Release Bullish 7/10 Entry $2.27 to $2.38 Now $2.15 −5.29% ▲ +4.85% +7.55% vs SPY
  5. Oct 16, 20264w ago 8-K Neutral 2/10 Entry $2.63 to $2.52 Now $2.15 −18.25% ▼ −4.18% −4.04% vs SPY
  6. Oct 5, 20266w ago 8-K Bullish 6/10 Entry $2.94 to $2.70 Now $2.15 −26.87% ▼ −8.16% −8.02% vs SPY
  7. Sep 15, 20268w ago 8-K Bullish 5/10 Entry $3.35 to $3.16 Now $2.15 −35.82% ▼ −5.67% −8.24% vs SPY
  8. Sep 14, 20269w ago 8-K Neutral 2/10 Entry $3.49 to $3.29 Now $2.15 −38.40% ▼ −5.73% −5.84% vs SPY
  9. Aug 17, 202613w ago 8-K Bullish 7/10 Entry $3.43 to $3.45 Now $2.15 −37.32% ▲ +0.58% +1.77% vs SPY
  10. Aug 17, 202613w ago Press Release Neutral 1/10 Entry $3.43 Now $2.15 −37.32% No price data
Showing 10 of 22

US Market Status

Market Closed · Opens in 6h 41m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Mar 19, 2026